Variants of Flavin-Containing Monooxygenase 3 Found in Subjects in an Updated Database of Genome Resources

被引:5
|
作者
Makiguchi, Miaki [1 ]
Shimizu, Makiko [1 ]
Yokota, Yuka [1 ]
Shimamura, Erika [1 ]
Hishinuma, Eiji [2 ,3 ]
Saito, Sakae [2 ,3 ]
Hiratsuka, Masahiro [2 ,3 ,4 ,5 ]
Yamazaki, Hiroshi [1 ,6 ]
机构
[1] Showa Pharmaceut Univ, Lab Drug Metab & Pharmacokinet, Tokyo, Japan
[2] Tohoku Univ, Adv Res Ctr Innovat Next Generat Med, Sendai, Japan
[3] Tohoku Univ, Tohoku Med Megabank Org, Sendai, Japan
[4] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Japan
[5] Tohoku Univ Hosp, Dept Pharmaceut Sci, Sendai, Japan
[6] Showa Pharmaceut Univ, Lab Drug Metab & Pharmacokinet, 3-3165 Higashi Tamagawagakuen, Machida, Tokyo 1948543, Japan
基金
日本学术振兴会;
关键词
FLAVIN-CONTAINING-MONOOXYGENASE-3; FMO3; GENE; TRIMETHYLAMINURIA; MUTATIONS;
D O I
10.1124/dmd.123.001310
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Single-nucleotide substitutions of human flavin-containing monooxygenase 3 (FMO3) identified in the whole-genome sequences of the updated Japanese population reference panel (now containing 38,000 subjects) were investigated. In this study, two stop codon mutations, two frameshifts, and 43 amino-acid-substituted FMO3 variants were identified. Among these 47 variants, one stop codon mutation, one frameshift, and 24 substituted variants were already recorded in the National Center for Biotechnology Information database. Functionally impaired FMO3 variants are known to be associated with the metabolic disorder trimethylaminuria; consequently, the enzymatic activities of the 43 substituted FMO3 variants were investigated. Twenty-seven recombinant FMO3 variants expressed in bacterial membranes had similar activities toward trimethylamine N-oxygenation (-75%-125%) to that of wild-type FMO3 (98 minutes21). However, six recombinant FMO3 variants (Arg51Gly, Val283Ala, Asp286His, Val382Ala, Arg387His, and Phe451Leu) had moderately decreased (-50%) activities toward trimethylamine N-oxygenation, and 10 recombinant FMO3 variants (Gly11Asp, Gly39Val, Met66Lys, Asn80Lys, Val151Glu, Gly193Arg, Arg387Cys, Thr453Pro, Leu457Trp, and Met497Arg) showed severely decreased FMO3 catalytic activity (<10%). Because of the known deleterious effects of FMO3 C-terminal stop codons, the four truncated FMO3 variants (Val187SerfsTer25, Arg238Ter, Lys416SerfsTer72, and Gln427Ter) were suspected to be inactive with respect to trimethylamine N-oxygenation. The FMO3 p.Gly11Asp and p.Gly193Arg variants were located within the conserved sequences of flavin adenine dinucleotide (positions 9-14) and NADPH (positions 191-196) binding sites, which are important for FMO3 catalytic function. Whole-genome sequence data and kinetic analyses revealed that 20 of the 47 nonsense or missense FMO3 variants had moderately or severely impaired activity toward N-oxygenation of trimethylaminuria.
引用
收藏
页码:884 / 891
页数:8
相关论文
共 50 条
  • [1] Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources
    Shimizu, Makiko
    Koibuchi, Natsumi
    Mizugaki, Ami
    Hishinuma, Eiji
    Saito, Sakae
    Hiratsuka, Masahiro
    Yamazaki, Hiroshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 38
  • [2] Simple confirmation methods for rare but impaired variants of human flavin-containing monooxygenase 3 (FMO3) found in an updated genome resource databank
    Shimizu, Makiko
    Makiguchi, Miaki
    Yokota, Yuka
    Shimamura, Erika
    Matsuta, Moegi
    Nakamura, Yuria
    Harano, Mizuki
    Yamazaki, Hiroshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2023, 53
  • [3] Rare but impaired flavin-containing monooxygenase 3 (FMO3) variants reported in a recently updated Japanese mega-databank of genome resources
    Shimizu, Makiko
    Makiguchi, Miaki
    Hishinuma, Eiji
    Saito, Sakae
    Hiratsuka, Masahiro
    Yamazaki, Hiroshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [4] Novel variants and haplotypes of human flavin-containing monooxygenase 3 gene associated with Japanese subjects suffering from trimethylaminuria
    Shimizu, Makiko
    Yoda, Hiromi
    Igarashi, Narumi
    Makino, Miki
    Tokuyama, Emi
    Yamazaki, Hiroshi
    XENOBIOTICA, 2019, 49 (10) : 1244 - 1250
  • [5] Flavin-containing monooxygenase 3 and human disease
    Motika, Meike S.
    Zhang, Jun
    Cashman, John R.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2007, 3 (06) : 831 - 845
  • [6] A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects
    Shimizu, Makiko
    Mizugaki, Ami
    Koibuchi, Natsumi
    Sango, Haruna
    Uenuma, Yumi
    Yamazaki, Hiroshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 41
  • [7] Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria
    Motika, Meike S.
    Zhang, Jun
    Zheng, Xueying
    Riedler, Kiersten
    Cashman, John R.
    MOLECULAR GENETICS AND METABOLISM, 2009, 97 (02) : 128 - 135
  • [8] Variants in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population
    Shimizu, Makiko
    Kobayashi, Yuko
    Hayashi, Shoko
    Aoki, Yuka
    Yamazaki, Hiroshi
    MOLECULAR GENETICS AND METABOLISM, 2012, 107 (03) : 330 - 334
  • [9] Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities
    Yamazaki, Hiroshi
    Shimizu, Makiko
    BIOCHEMICAL PHARMACOLOGY, 2013, 85 (11) : 1588 - 1593
  • [10] Genetic variants of flavin-containing monooxygenase 3 (FMO3) derived from Japanese subjects with the trimethylaminuria phenotype and whole-genome sequence data from a large Japanese database
    Shimizu, Makiko
    Yoda, Hiromi
    Nakakuki, Komei
    Saso, Aoi
    Saito, Iria
    Hishinuma, Eiji
    Saito, Sakae
    Hiratsuka, Masahiro
    Yamazaki, Hiroshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (05) : 334 - 339